Trends in systemic therapy for malignant peripheral nerve sheath tumors

1. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005; 65(2):205–211.10.1212/01.wnl.0000168830.79997.131604378716043787Open DOISearch in Google Scholar

2. Widemann BC. Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr. Oncol. Rep. 2009; 11(4),322–328.10.1007/s11912-009-0045-z668940019508838Open DOISearch in Google Scholar

3. Farid M, Demicco EG, Garcia R et al. Malignant peripheral nerve sheath tumors. Oncologist. 2011; 19(2),193–201.10.1634/theoncologist.2013-0328392679424470531Open DOISearch in Google Scholar

4. Papalia H, Audic F, Rivière GR, Verschuur A, André N. Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas. Ecancermedicalscience. 2018; 12:862.10.3332/ecancer.2018.862611398430174724Search in Google Scholar

5. Dombi E, Baldwin A, Marcus LJ et al. Activity of Selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med. 2016; 375(26):2550–2560.10.1056/NEJMoa1605943550859228029918Search in Google Scholar

6. Vaassen P, Dürr N, Röhrig A, Willing R, Rosenbaum T. Trametinib induces neurofibroma shrinkage and enables surgery. Neuropediatrics. 2019; 50(5):300–303.10.1055/s-0039-169183031141829Open DOISearch in Google Scholar

7. Dunn GP, Spiliopoulos K, Plotkin SR et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1 J Neurosurg. 2013; 118(1):142–148.10.3171/2012.9.JNS101610Search in Google Scholar

8. Hirbe AC, Cosper PF, Dahiya S, Van Tine BA. Neoadjuvant ifosfamide and epirubicin in the treatment of malignant peripheral nerve sheath tumors. Sarcoma. 2017; 2017:3761292.2854678210.1155/2017/3761292543590328546782Search in Google Scholar

9. Prudner BC, Ball T, Rathore R, Hirbe AC. Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives. Neuro-Oncology Advances XX(XX). 2019; 1–10. doi:10.1093/noajnl/vdz047.10.1093/noajnl/vdz047731706232642731Open DOISearch in Google Scholar

10. Wang D, Zhang Q, Eisenberg BL et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of radiation therapy oncology group RTOG-0630 trial. J Clin Oncol. 2015; 33(20):2231–2238.10.1200/JCO.2014.58.5828448634225667281Search in Google Scholar

11. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006; 43(4):289–294.10.1136/jmg.2005.036319256322316155191Search in Google Scholar

12. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11(7):1269–1275.10.1200/JCO.1993.11.7.12698315424Open DOISearch in Google Scholar

13. Albritton KH, Rankin C, Coffin CM et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol (Meeting Abstracts). 2006; (no.18_suppl):9518.10.1200/jco.2006.24.18_suppl.9518Search in Google Scholar

14. Widemann BC, Reinke DK, Helman LJ et al. SARC016: phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol (Meeting Abstracts). 2016; 34(suppl; abstr 11053).10.1200/JCO.2016.34.15_suppl.11053Search in Google Scholar

15. Manji GA, Tine BAV, Lee SM et al. Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas. J Clin Oncol. 2019; 37(15_suppl):11055–11055.10.1200/JCO.2019.37.15_suppl.11055Search in Google Scholar

16. Wu J, Williams JP, Rizvi TA et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell. 2008; 13(2),105–116.10.1016/j.ccr.2007.12.027284669918242511Open DOISearch in Google Scholar

17. Mahller YY, Vaikunth SS, Currier MA et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol. Ther. 2007; 15(2), 279–286.10.1038/sj.mt.630003817235305Open DOISearch in Google Scholar